Pegfilgrastim, a sustained-duration form of filgrastim, significantly improves neutrophil recovery after autologous marrow transplantation in rhesus macaques

Bone Marrow Transplantation

Volumn 32, Issue 4, 2003, Pages 399-404

  Farese, A M ^a   Yang, B B ^b   Roskos, L ^b   Stead, R B ^b   MacVittie, T J ^a  

^a UNIVERSITY OF MARYLAND   (United States)

^b AMGEN INC   (United States)

Author keywords

Myelosupression; Neutrophil; Pegfilgrastim; Rhesus

Indexed keywords

ANTIINFECTIVE AGENT; ENROFLOXACIN; GENTAMICIN; MYELOABLATIVE AGENT; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; AUTOLOGOUS BONE MARROW TRANSPLANTATION; AUTOREGULATION; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE DURATION; DISEASE MODEL; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFICACY; MALE; NEUTROPENIA; NEUTROPHIL; NONHUMAN; PHARMACOLOGICAL PARAMETERS; PRIORITY JOURNAL; RADIATION DOSE; RHESUS MONKEY; SINGLE DRUG DOSE;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE MARROW CELLS; BONE MARROW TRANSPLANTATION; COHORT STUDIES; CYTOKINES; FILGRASTIM; MACACA MULATTA; MALE; NEUTROPENIA; NEUTROPHILS; RECOMBINANT PROTEINS; TIME FACTORS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, AUTOLOGOUS;

EID: 0041887012     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1704156     Document Type: Article

References (21)

1. Welte K, Gabrilove J, Bronchud MH et al. Filgrastim (r-metHuG-CSF): the first 10 years. Blood 1996; 88: 1907-1929.
2. Morstyn G, Campbell L, Souza LM et al. Effect of granulocyte colony stimulating factor on neutropenia induced by cytotoxic chemotherapy. Lancet 1988; 1: 668-672.
3. Sheridan WP, Morstyn G, Wolf M et al. Granulocyte colony-stimulating factor and neutrophil recovery after high-dose chemotherapy and autologous bone marrow transplantation. Lancet 1989; 2: 891-895.
4. Crawford J, Ozer H, Stoller R et al. Reduction by granulocyte-colony stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer. N Engl J Med 1991; 325: 164-170.
5. Bishop MR, Tarantolo SR, Geller RB et al. A randomized, double-blind trial of filgrastim (granulocyte colony-stimulating factor) versus placebo following allogeneic blood stem cell transplantation. Blood 2000; 96: 80-85.
6. Nienhuis AW, Donahue RE, Karlsson S et al. Recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF) shortens the period of neutropenia after autologous bone marrow transplantation in a primate model. J Clin Invest 1987; 80: 573-577.
7. Monroy RL, Skelly RR, MacVittie TJ et al. The effect of recombinant GM-CSF on the recovery of monkeys transplanted with autologous bone marrow. Blood 1987; 70: 1696-1699.
8. Molineux G, Kinstler O, Briddell B et al. A new form of filgrastim with sustained duration in vivo and enhanced ability to mobilize PBPC in both mice and humans. Exp Hematol 1999; 27: 1724-1734.
9. Van der Auwera P, Platzer E, Xu ZX et al. Pharmacodynamics and pharmacokinetics of single doses of subcutaneous pegylated human G-CSF mutant (Ro 25-8315) in healthy volunteers: comparison with single and multiple daily doses of filgrastim. Am J Hematol 2001; 66: 245-251.
10. Lord BI, Woolford LB, Molineux G. Kinetics of neutrophil production in normal and neutropenic animals during the response to filgrastim (r-metHu G-CSF) or filgrastim SD/01 (Peg-r-metHu G-CSF). Clin Cancer Res 2001; 7: 2085-2090.
11. Viens P, Chabannon C, Pouillart P et al. Randomized, controlled, dose-range study of Ro 25-8315 given before and after a high-dose combination chemotherapy regimen in patients with metastatic or recurrent breast cancer patients. J Clin Oncol 2002; 20: 24-36.
12. Johnston E, Crawford J, Blackwell S et al. Randomized dose-escalation study of SD/01 compared with daily filgrastim in patients receiving chemotherapy. J Clin Oncol 2000; 18: 2522-2528.
13. Holmes FA, Jones SE, O'Shaughnessy J et al. Comparable efficacy and safety profiles of once-per-cycle pegfilgrastim and daily injection filgrastim in chemotherapy-induced neutropenia: a multicenter dose-finding study in women with breast cancer. Ann Oncol 2002; 13: 903-909.
14. Green MD, Koelbl H, Baselga J et al. A randomized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy. Ann Oncol 2003; 14: 29-35.
15. Holmes FA, O'Shaughnessy JA, Vukelja S et al. Blinded, randomized, multicenter study to evaluate single administration pegfilgrastim one per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high-risk stage II or stage III/IV breast cancer. J Clin Oncol 2002; 20: 727-731.
16. Vose JM, Crump M, Lazarus H et al. Randomized, multicenter, open-label study of pegfilgrastim compared with daily filgrastim after chemotherapy for lymphoma. J Clin Oncol 2003; 21: 519.
17. de Haan G, Ausema A, Wilkens M et al. Efficient mobilization of haematopoietic progenitors after a single injection of pegylated recombinant human granulocyte colony-stimulating factor in mouse strains with distinct marrow-cell pool sizes. Br J Haematol 2000; 110: 638-646.
18. The Institute of Laboratory Animal Resources, National Research Council: Guide for the Care and Use of Laboratory Animals, Vol. 86. National Institutes of Health: Washington, DC, 1996.
19. Cheung EN, Cosenza M, Lopez O et al. Modeling of r-metHuG-CSF-SD/01 (SD/01) mediated granulopoiesis in normal animals with mathematical extrapolation to neutropenic settings. Blood 1998; 92 (Suppl. 1): 379.
20. Roskos LK, Yang B, Schwab G et al. Cytokinetic model of rmethHuG-CSF-SD/01 (SD/01) mediated granulopoiesis and the 'self-regulation' of SD/01 elimination in non-small cell lung cancer. Blood 1998; 92 (Suppl.): 507A.
21. Farese AM, Casey DB, Vigneulle RM et al. A single dose of pegylated leridistim significantly improves neutrophil recovery in sublethally irradiated rhesus macaques. Stem Cells 2001; 19: 514-521.